The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy.

Xiao-Han Zhao,Wen-Bin Shen,Duo Wang,He-Song Wang,Chun-Yang Song,Wen-Zhao Deng

Frontiers in oncology（2023）

引用 1|浏览4

暂无评分

摘要

R/M ESCC patients with low CONUT/SIS score have better prognosis, higher objective response rate, lower incidence of immune-related toxic and side effects after receiving immunotherapy as second-line therapy. CONUT scores and SIS scores may be reliable prognostic indicators for patient receiving immunotherapy as second-line therapy for R/M ESCC.

查看译文

关键词

esophageal squamous cell carcinoma, second-line treatment, immune checkpoint inhibitors, controlling nutritional status, systemic inflammation score, prognosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要